Strategic Collaboration Recent partnership with the University of Pittsburgh to advance BT-Reveal Early Pancreatic Cancer Test presents a joint development and validation opportunity. Leverage the collaboration to cross-sell AI-powered genomic analysis capabilities to academic medical centers and translational research groups pursuing early cancer detection.

AI-Driven Advantage Two proprietary AI-powered genomic analysis platforms position Breakthrough Genomics as a differentiated provider for high-throughput, accurate genomic interpretation. Target biopharma, CROs, and diagnostic developers seeking scalable, AI-enhanced data interpretation to accelerate study timelines and improve diagnostic accuracy.

Growth Target Revenue footprint in the low to mid multi-millions, with an employee base under 100, indicates agility and potential for scalable partnerships rather than large enterprise deployments. Pursue pilot programs with mid-sized labs, hospitals, and research institutes to demonstrate ROI and build reference sites.

Pancreatic Cancer Focus BT-Reveal Early Pancreatic Cancer Test focus signals a niche entry point in oncology diagnostics. Develop outreach to cancer centers, GI clinics, and translational research groups seeking early detection tools, while offering integration with existing sequencing workflows.

Tech Ecosystem Fit Adoption of modern tech stack and digital channels (Open Graph, RSS, Google Workspace, LinkedIn) suggests readiness for partner enablement, co-marketing, and developer-friendly integrations. Propose joint marketing programs, technical webinars, and API/data integration discussions to accelerate collaborations.